Heteroconjugate antibodies enhance cell-mediated anti-herpes simplex virus immunity in vivo

• Published in: International immunology Vol. 4; no. 3; p. 417
• Main Authors: Voss, L M, David, C S, Showalter, S D, Paya, C V, Leibson, P J
• Format: Journal Article
• Language: English
• Published: England 01.03.1992
• Subjects: Animals; Animals, Newborn; Antibodies, Monoclonal - administration & dosage; Antibodies, Viral - administration & dosage; Antigens, Differentiation, T-Lymphocyte; CD3 Complex; Herpes Simplex - immunology; Herpes Simplex - microbiology; Herpes Simplex - therapy; Immunity, Cellular; Mice; Receptors, Antigen, T-Cell; Simplexvirus - immunology; Simplexvirus - physiology; Virus Replication
• ISSN: 0953-8178
• DOI: 10.1093/intimm/4.3.417

Heteroconjugate antibodies are generated by covalently linking two mAbs with different specificities. When anti-CD3 mAb, capable of activating effector T cells, is coupled to anti-herpes simplex virus (HSV) mAb, which binds HSV antigens on virally-infected target cells, the resulting heteroconjugate antibody can be used in vitro to enhance anti-HSV immunity. Specifically, these heteroconjugate antibodies can augment anti-HSV immunity among lymphocytes previously lacking cytotoxicity against HSV-infected target cells. However, the efficacy of these specialized reagents in enhancing anti-HSV immunity in vivo has not been determined. We report here that anti-HSV heteroconjugates used in an adoptive transfer murine model of HSV-1 infection inhibited HSV replication in vivo and improved long-term survival. These results demonstrate that heteroconjugate antibodies have a potential therapeutic role in enhancement of anti-HSV immunity.